Overview
- Samsung Biologics America signed a definitive agreement to purchase the Rockville, Maryland manufacturing assets from GSK for $280 million.
- Closing is anticipated toward the end of Q1 2026, subject to customary conditions.
- The facility includes two cGMP plants with a combined 60,000 liters of drug‑substance capacity supporting both clinical and commercial production.
- Samsung will retain more than 500 employees, continue existing product manufacturing, and invest to expand capacity and upgrade technology.
- Samsung plans to integrate the site into its global operations to offer multi‑site options, while GSK says the divestment secures U.S. manufacture of two medicines and aligns with its $30 billion U.S. R&D and manufacturing commitment.